[Waldenstrôm's macroglobulinemia. Developmental and prognostic study].

Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenström's Macroglobulinemia: a case report. Cases J (2008) 0.75

A Case of Nephrotic Syndrome With Minimal-Change Disease and Waldenstrom's Macroglobulinemia. J Clin Med Res (2013) 0.75

Symptoms of anxiety and depression in family members of intensive care unit patients: ethical hypothesis regarding decision-making capacity. Crit Care Med (2001) 3.98

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol (1989) 2.43

French intensivists do not apply American recommendations regarding decisions to forgo life-sustaining therapy. Crit Care Med (2001) 2.39

Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res (1996) 1.95

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1998) 1.90

T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72

Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol (2001) 1.65

Sequences and diversity of human T cell receptor beta chain variable region genes. J Exp Med (1986) 1.62

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol (1996) 1.47

Expression, structure, and function of the CD23 antigen. Adv Immunol (1991) 1.46

Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol (1998) 1.44

Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest (1992) 1.43

T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol (1994) 1.43

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

In vitro sensitivity of normal and leukemic myeloid clonogenic cells to hyperthermia: absence of selective effect. Exp Hematol (1989) 1.38

Evidence for a cytotoxic T-lymphocyte alveolitis in human immunodeficiency virus-infected patients. AIDS (1988) 1.37

Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol (1989) 1.33

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol (1998) 1.32

Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS (1997) 1.30

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood (1991) 1.29

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia (1997) 1.28

Compliance with triage to intensive care recommendations. Crit Care Med (2001) 1.28

Overexpression of cyclin D2 in chronic B-cell malignancies. Blood (1995) 1.26

Soluble CD23 (Fc epsilon RII) and interleukin 1 synergistically induce early human thymocyte maturation. J Exp Med (1990) 1.26

CD4+CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood (1992) 1.23

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia (2003) 1.21

Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood (1998) 1.21

Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med (1998) 1.17

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood (2000) 1.12

Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia (1997) 1.10

T-lymphocyte colonies in the lymphoproliferative disorders. Immunology (1978) 1.09

Acute renal failure following collective intoxication by Cortinarius orellanus. Intensive Care Med (1990) 1.07

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial. Cancer (1999) 1.06

[Chromosome analyses in idiopathic acquired sideroblastic anemia. A study of 6 cases]. Nouv Rev Fr Hematol (1967) 1.06

Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood (1998) 1.04

Critical analysis of T cell subset and function evaluation in patients with persistent generalized lymphadenopathy in groups at risk for AIDS. Clin Exp Immunol (1984) 1.04

A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood (1991) 1.04

Internalization of HIV glycoprotein gp120 is associated with down-modulation of membrane CD4 and p56lck together with impairment of T cell activation. J Immunol (1992) 1.02

Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway. J Clin Invest (1990) 1.02

Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood (1999) 1.01

Fully functional NK cells after unrelated cord blood transplantation. Leukemia (2009) 1.01

Increased lung epithelial permeability in HIV-infected patients with isolated cytotoxic T-lymphocytic alveolitis. Am Rev Respir Dis (1990) 1.00

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood (1997) 0.99

Genetic control of sensitivity to Moloney leukemia virus in mice. IV. Phenotypic heterogeneity of the leukemic mice. J Immunol (1980) 0.98

Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol (2000) 0.98

CD34-expressing human thymocyte precursors proliferate in response to interleukin-7 but have lost myeloid differentiation potential. Blood (1993) 0.97

Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody. Cell Immunol (1990) 0.97

Models for clonal evolutions: a study of chronic myelogenous leukemia. Am J Hum Genet (1966) 0.96

Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia (1993) 0.96

Epidemic Pseudomonas aeruginosa serotype O16 bacteremia in hematology-oncology patients. J Clin Microbiol (1989) 0.95

Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes. J Immunol Methods (1992) 0.95

Human trophoblast cells express CD4 and are permissive for productive infection with HIV-1. Clin Exp Immunol (1992) 0.95

Alveolar CD8+CD57+ lymphocytes in human immunodeficiency virus infection produce an inhibitor of cytotoxic functions. Am J Respir Crit Care Med (1994) 0.95

Evidence for expression of two distinct T cell receptor beta-chain transcripts in a human diphtheria toxoid-specific T cell clone. J Immunol (1988) 0.94

Isolation of an early T-cell precursor (CFU-TL) from human bone marrow. Blood (1990) 0.94

A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol (1996) 0.94

Fournier's gangrene during induction treatment of acute promyelocytic leukemia, a case report. Ann Hematol (1998) 0.94

Annotation: Subacute and chronic myelomonocytic leukaemia: a distinct haematological entity. Br J Haematol (1976) 0.94

Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features. Histopathology (1988) 0.93

CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups. J Infect Dis (1999) 0.93

Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol (1999) 0.93

MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer (1996) 0.91

Genetic control of sensitivity to Moloney leukemia virus in mice. II. Mapping of three resistant genes within the H-2 complex. J Immunol (1979) 0.91

Expression of MHC class II and Tac antigens on IL2-activated human T cell clones that can stimulate in MLR, AMLR, PLT and can present antigen. Hum Immunol (1986) 0.91

Modern clinical testing strategies in cobalamin and folate deficiency. Semin Hematol (1999) 0.90

Letter: HL-A and pernicious anemia. N Engl J Med (1975) 0.89

Immunoregulatory effects of a suppressor factor from healthy pregnant women's lymphocytes after progesterone induction. Cell Immunol (1989) 0.89

Waldenström's macroglobulinaemia in a bird breeder: a case history with pulmonary involvement and antibody activity of the monoclonal IgM to canary's droppings. Clin Exp Immunol (1987) 0.89

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia (2003) 0.89

Spontaneous remission in adult acute leukemia. Cancer (1985) 0.88

Effect of folate and cobalamin compounds on the deoxyuridine suppression test in vitamin B12 and folate deficiency. Blood (1978) 0.88

Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer (1995) 0.88

Prediction of the response to chemotherapy in acute leukemia. Cancer (1975) 0.87

N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant (1993) 0.87

Disseminated superficial porokeratosis after autologous bone marrow transplantation. Bone Marrow Transplant (1997) 0.87

Identification of a pure splenic form of chronic lymphocytic leukaemia. Br J Haematol (1979) 0.87

Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal. Blood (1987) 0.86

Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia. Leukemia (1987) 0.86

IL-4 release by human leukemic and activated normal basophils. J Immunol (1993) 0.86

MS-8209, a new Amphotericin B derivative that inhibits HIV-1 replication in vitro and restores T-cell activation via the CD3/TcR in HIV-infected CD4+ cells. AIDS (1991) 0.86

Detection of apoptosis at the single-cell level by direct incorporation of fluorescein-dUTP in DNA strand breaks. Biotechniques (1996) 0.86

T-lymphocyte progenitors in man: phenotypic characterization of blood and bone marrow T-colony forming cells. Immunology (1985) 0.85

[Subacute myelo-monocytic leukemia. Study of 27 cases and review of the literature]. Sem Hop (1972) 0.85

Effects of the molecular weight of peg molecules (8, 20 and 35 KDA) on cell function and allograft survival prolongation in pancreatic islets transplantation. Transplant Proc (2006) 0.85

HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant (2008) 0.85

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU. Qual Life Res (1996) 0.85

Splenic marginal zone lymphoma with or without plasmacytic differentiation. Am J Surg Pathol (2000) 0.85

Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol (1992) 0.85

Normal human bone marrow cultures in vitro: cellular composition and maturation of the granulocytic colonies. Br J Haematol (1977) 0.85

[Pseudolymphoma and lymphoproliferative syndromes in Gougerot-Sjögren syndrome (author's transl)]. Sem Hop (1979) 0.85

[In vitro effect of antibiotics against hospital strains of Acinetobacter baumanii]. Pathol Biol (Paris) (1989) 0.85